Characteristics and outcome of enhancing foci followed on breast MRI with management implications

Ha, Ruoshui; Sung, Janice S.; Lee, Carol H.; Comstock, Christopher; Wynn, Ralph; Morris, Elizabeth A.

doi:10.1016/j.crad.2014.02.007

Cited by 35 publications

(39 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Contrast‐enhanced MR can be regarded as a functional imaging technique predicated on blood flow changes in lesions with respect to healthy tissue. As such, it can highlight tumors without solely relying on anatomical changes, resulting in the ability to detect cancers only a few millimeters in size …”

Section: Discussionmentioning

confidence: 99%

“…As such, it can highlight tumors without solely relying on anatomical changes, resulting in the ability to detect cancers only a few millimeters in size. 29 A major strength of this work was the complete separation of the training and test datasets, ensuring that the potential for overfitting is minimized. Previous work either involved no further validation of the model developed, 17 or the utilization of all cases in feature selection 18 ; both approaches can be considered suboptimal.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Characterization of Sub‐1 cm Breast Lesions Using Radiomics Analysis

Gibbs

Onishi

Sadinski

et al. 2019

Magnetic Resonance Imaging

View full text Add to dashboard Cite

Background Small breast lesions are difficult to visually categorize due to the inherent lack of morphological and kinetic detail. Purpose To assess the efficacy of radiomics analysis in discriminating small benign and malignant lesions utilizing model free parameter maps. Study Type Retrospective, single center. Population In all, 149 patients, with a total of 165 lesions scored as BI‐RADS 4 or 5 on MRI, with an enhancing volume of <0.52 cm3. Field Strength/Sequence Higher spatial resolution T1‐weighted dynamic contrast‐enhanced imaging with a temporal resolution of ~90 seconds performed at 3.0T. Assessment Parameter maps reflecting initial enhancement, overall enhancement, area under the enhancement curve, and washout were generated. Heterogeneity measures based on first‐order statistics, gray level co‐occurrence matrices, run length matrices, size zone matrices, and neighborhood gray tone difference matrices were calculated. Data were split into a training dataset (~75% of cases) and a test dataset (~25% of cases). Statistical Tests Comparison of medians was assessed using the nonparametric Mann–Whitney U‐test. The Spearman rank correlation coefficient was utilized to determine significant correlations between individual features. Finally, a support vector machine was employed to build multiparametric predictive models. Results Univariate analysis revealed significant differences between benign and malignant lesions for 58/133 calculated features (P < 0.05). Support vector machine analysis resulted in areas under the curve (AUCs) ranging from 0.75–0.81. High negative (>89%) and positive predictive values (>83%) were found for all models. Data Conclusion Radiomics analysis of small contrast‐enhancing breast lesions is of value. Texture features calculated from later timepoints on the enhancement curve appear to offer limited additional value when compared with features determined from initial enhancement for this patient cohort. Level of Evidence: 4 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2019;50:1468–1477.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Characterization of Sub‐1 cm Breast Lesions Using Radiomics Analysis

Gibbs

Onishi

Sadinski

et al. 2019

Magnetic Resonance Imaging

View full text Add to dashboard Cite

show abstract

“…In this study, foci constituted 24% of all lesions. Cancer detection rate of foci are variable (0.6%-30.7%) in the literature (12)(13)(14)(15)(16). In this study, 21% of the foci were malignant.…”

Section: Discussionmentioning

confidence: 49%

Lesion characteristics, histopathologic results, and follow-up of breast lesions after MRI-guided biopsy

Taşkın

Soyder²,

Tanyeri³

et al. 2017

Diagn Interv Radiol

View full text Add to dashboard Cite

M agnetic resonance imaging (MRI) is a widely used diagnostic tool for breast imaging in daily practice, with its high sensitivity to detect primary, recurrent, and residual breast cancer. Breast MRI serves as a reliable problem-solving tool in case of inconclusive mammography and ultrasonography (US) findings. It can be used to monitor the results of neoadjuvant chemotherapy and it may also contribute to preoperative evaluation of known lesions. With increasing use of MRI, number of breast lesions visible only on MRI and need for MRI-guided breast biopsy have increased (1). Second-look US can also be used for re-evaluation of these lesions; because US-guided biopsy is an easier, cheaper, and faster method if these lesions are visible on second-look US. According to a recently published meta-analysis, lesion detection rates with second-look US are variable in the literature (22.6%-82.1%). Mass lesions and malignant lesions were more likely to be detected at second-look US; average detection rates were 66% for masses, 29% for non-mass-like enhancement (NME) (2, 3). However, focal or NME lesions, which are less detectable than masses on second-look US, require MRI-guided biopsy in the majority of cases. According to the MRI-guided biopsy series in the literature, approximately 25%-35% of these lesions are diagnosed as malignant (4-9).Within this context, the aim of the present study is to assess the effectiveness of MRI-guided 10 Gauge (G) vacuum-assisted breast biopsies (VABB) performed at our institution and to examine the relationship between lesion characteristics and histopathologic results. B R E A S T I MAG I N G O R I G I N A L A R T I C L E PURPOSEWe aimed to assess the effectiveness of magnetic resonance imaging (MRI)-guided vacuum-assisted breast biopsy (VABB), evaluate and compare the characteristics and histopathologic findings of lesions, and overview the follow-up results of benign lesions. METHODSMRI findings and histopathologic results of breast lesions biopsied by MRI-guided VABB between 2013 and 2016 were retrospectively analyzed. MRI findings closely related with malignancy were investigated in particular. Follow-up results of benign lesions were evaluated. RESULTSMRI-guided VABB was applied to 116 lesions of 112 women. Of the lesions, 75 (65%) were benign, while 41 (35%) were malignant. Segmental (94%), clustered (89%), and clustered ring (67%) nonmass-like enhancement patterns were found to be more related with malignancy. False-negative rate of MRI-guided VABB was 12%, underestimation rate was 21%. One of the 54 followed-up benign lesions had a malignant result. CONCLUSION MRI-guided VABB is a reliable method for the diagnosis of breast lesions that are positive only on MRI. Follow-up results show that cancer detection rate is low for radio-pathologically concordant lesions. Further multicenter studies with larger patient population are needed to elucidate these results.You may cite this article as: Taşkın F, Soyder A, Tanyeri A, Öztürk VS, Ünsal A. Lesion characteristics, histopathologic r...

show abstract

“…Magnetic resonance imaging-detected lesions measuring less than 5 mm had a 3% (1 of 37 lesions) frequency of FIGURE 3. A retrospective study of 111 patients with 136 foci by Ha et al 27 showed that kinetics were not useful in distinguishing benign from malignant foci. A, Postcontrast subtraction T1-weighted image shows a unique but benign-appearing focus (arrow), which correlates with high signal (B, arrow) on fat-saturated T2-weighted image and had persistent kinetics (C, arrow).…”

Section: Focimentioning

confidence: 99%

Breast Imaging Reporting and Data System Category 3 for Magnetic Resonance Imaging

Lee

2014

Topics in Magnetic Resonance Imaging

View full text Add to dashboard Cite

The Breast Imaging Reporting and Data System (BI-RADS) category 3 signifies a probably benign finding and should be reserved for those findings that have a less than 2% risk of malignancy. There are limited data defining the use of this category in magnetic resonance imaging (MRI) and the imaging features of probably benign lesions are not well defined. Most recent studies have shown that the frequency of use of BI-RADS 3 is comparable with that reported in mammography and ultrasound and that the rate of malignancy is within the targeted range. Several findings, once assessed as BI-RADS 3, are now known to represent benign entities, such as variations of background parenchymal enhancement and intramammary lymph nodes. A subset of masses, foci, and nonmass enhancement can appropriately be assigned BI-RADS 3 on baseline MRI. The BI-RADS 3 is most appropriately used for round, dot-like foci, which are unique and separate from background parenchymal enhancement and for oval masses with circumscribed margins and homogeneous enhancement, such as those typically seen in incidental fibroadenomas. The BI-RADS 3 may also be appropriate for a focal or regional distribution of nonmass enhancement without suspicious features.

show abstract

Characteristics and outcome of enhancing foci followed on breast MRI with management implications

Cited by 35 publications

References 18 publications

Characterization of Sub‐1 cm Breast Lesions Using Radiomics Analysis

Characterization of Sub‐1 cm Breast Lesions Using Radiomics Analysis

Lesion characteristics, histopathologic results, and follow-up of breast lesions after MRI-guided biopsy

Breast Imaging Reporting and Data System Category 3 for Magnetic Resonance Imaging

Contact Info

Product

Resources

About